piracetam has been researched along with Dementia in 42 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of piracetam (Nootropil, UCB6215) on mental functions and on regional cerebral blood flow (rCBF) were investigated in eight patients in the presenile age who displayed symptoms of moderate dementia." | 9.04 | Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia. ( Fransson, M; Gustafson, L; Johanson, M; Maximilian, VA; Risberg, J, 1978) |
| "To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease, or unclassified dementia, or cognitive impairment not fulfilling the criteria for dementia." | 8.81 | Piracetam for dementia or cognitive impairment. ( Flicker, L; Grimley Evans, G, 2001) |
| "To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease or unclassified dementia or cognitive impairment not fulfilling the criteria for dementia." | 8.80 | Piracetam for dementia or cognitive impairment. ( Flicker, L; Grimley Evans, J, 2000) |
| "Patients with cognitive decline from Alzheimer's disease and/or cerebrovascular origin have received the drug, in the first 4 weeks in 4800, later 2400 mg daily doses." | 6.69 | [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia]. ( Paksy, A; Tariska, P, 2000) |
| " It covers firstly the general problems of stroke, dementia and 'common symptoms' of the elderly, and then looks in detail at those compounds which have to date attracted most attention (ergot derivatives, cinnarizine, flunarizine, vincamine, eburnamonine, naftidrofuryl, oxpentifylline, piracetam and citicoline), as well as those which are currently considered investigational (choline and lecithin)." | 6.15 | 'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders. ( Spagnoli, A; Tognoni, G, 1983) |
| "The effects of piracetam (Nootropil, UCB6215) on mental functions and on regional cerebral blood flow (rCBF) were investigated in eight patients in the presenile age who displayed symptoms of moderate dementia." | 5.04 | Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia. ( Fransson, M; Gustafson, L; Johanson, M; Maximilian, VA; Risberg, J, 1978) |
| "To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease, or unclassified dementia, or cognitive impairment not fulfilling the criteria for dementia." | 4.81 | Piracetam for dementia or cognitive impairment. ( Flicker, L; Grimley Evans, G, 2001) |
| "A meta-analysis has been performed including nineteen double blind, placebo controlled studies with piracetam in patients suffering from dementia or cognitive impairment in the elderly." | 4.81 | Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. ( Danniau, A; Ferris, SH; Kurz, A; Waegemans, T; Wilsher, CR; Winblad, B, 2002) |
| "To determine the clinical efficacy of piracetam for the features of dementia or cognitive impairment, classified according to the major subtypes of dementia: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease or unclassified dementia or cognitive impairment not fulfilling the criteria for dementia." | 4.80 | Piracetam for dementia or cognitive impairment. ( Flicker, L; Grimley Evans, J, 2000) |
| " He improved rapidly on levetiracetam and lorazepam, was discharged and received a diagnosis of dementia by his community mental health team shortly afterwards, based on chronic short-term memory loss, functional decline and MRI changes." | 3.85 | Intermittent catatonia and complex automatisms caused by frontal lobe epilepsy in dementia. ( George, R; Langford, A, 2017) |
| " The increased risk associated with piracetam may reflect awareness of memory problems before any diagnosis of dementia has been made." | 3.75 | Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. ( Beckett, N; Bulpitt, C; de Vernejoul, MC; Fletcher, A; Gainsborough, N; Geneva, M; Lu, FH; Peters, R; Poulter, R; Tzekova, M; Williams, B, 2009) |
| "Oxiracetam, a new substance found to be a nootropic in experimental pharmacological studies, was tested in three clinical trials: a single rising dose tolerance and dose-finding study with quantitative pharmaco-electroencephalogram (pharmaco-EEG) and quantitative pharmacopsychology in healthy volunteers; a dose-finding study, at three dose levels for 3 months, with quantitative pharmaco-EEG in mild to moderate dementia patients; and a safety and efficacy study with increasing dosages for 12 weeks with subjective and objective tests in elderly patients with dementia." | 3.67 | CNS pharmacology and clinical therapeutic effects of oxiracetam. ( Itil, KZ; Itil, TM; Menon, GN; Songar, A, 1986) |
| "The effects of exifone (ADLONE), hexahydro-2,3,4,3',4',5'-benzophenone, were tested in two models of memory in the mouse: habituation of exploratory activity and antagonism of amnesia induced by scopolamine in a passive avoidance task." | 3.67 | The effects of exifone, a new agent for senile memory disorder, on two models of memory in the mouse. ( Avril, I; Doumont, G; Lenègre, A; Porsolt, RD; Stéru, L, 1987) |
| "13 patients with psycho-organic syndrome (POS) and 10 patients with dementia (senile, Alzheimer, multi-infarct) were treated with drugs considered to influence the neuronal turnover of acetylcholine (Phosphatidylcholine, piracetam, S-adenosylmethionine) for 30 days and compared in respect of CSF ACh levels, reaction times to simple visual stimuli (TRS-V) and to simple hearing stimuli (TRS-H) and scores on the Sandoz Clinical Assessment Geriatric (SCAG) rating scale." | 3.67 | Involutional dementias: new perspectives. ( Borromei, A; Gaggi, R; Giancola, LC, 1985) |
| "Patients with cognitive decline from Alzheimer's disease and/or cerebrovascular origin have received the drug, in the first 4 weeks in 4800, later 2400 mg daily doses." | 2.69 | [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia]. ( Paksy, A; Tariska, P, 2000) |
| "2 years, showed statistically significant differences between piracetam therapy at a dosage of 3 X 1600 mg per day und placebo after a six week peroral therapy while no statistically significant differences between piracetam therapy at a dosage of 3X800 mg per day and placebo were found." | 2.64 | [On the dose-effect relationship in the therapy with piracetam (author's transl)]. ( Kretschmar, CH; Kretschmar, JH, 1976) |
| "Levetiracetam was the most commonly used initial medication, with the majority (73%) of patients treated achieving partial or complete seizure control." | 1.46 | The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy. ( Chemali, Z; Gholipour, T; Mitchell, S; Sarkis, RA, 2017) |
| "Dementia was classified into vascular (VaD) and degenerative dementia." | 1.42 | The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan. ( Chou, YJ; Chow, LH; Hu, HY; Huang, N; Li, CP; Wang, PN; Wu, CY, 2015) |
| "Dementia is one of the age related mental problems and a characteristic symptom of various neurodegenerative disorders including Alzheimer's disease." | 1.33 | Evaluation of nootropic potential of Ocimum sanctum Linn. in mice. ( Joshi, H; Parle, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (57.14) | 18.7374 |
| 1990's | 8 (19.05) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 3 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| George, R | 1 |
| Langford, A | 1 |
| Wu, CY | 1 |
| Hu, HY | 1 |
| Chow, LH | 1 |
| Chou, YJ | 1 |
| Huang, N | 1 |
| Wang, PN | 1 |
| Li, CP | 1 |
| Gholipour, T | 1 |
| Mitchell, S | 1 |
| Sarkis, RA | 1 |
| Chemali, Z | 1 |
| Peters, R | 1 |
| Beckett, N | 1 |
| Geneva, M | 1 |
| Tzekova, M | 1 |
| Lu, FH | 1 |
| Poulter, R | 1 |
| Gainsborough, N | 1 |
| Williams, B | 1 |
| de Vernejoul, MC | 1 |
| Fletcher, A | 1 |
| Bulpitt, C | 1 |
| Moretti, R | 1 |
| Torre, P | 1 |
| Antonello, RM | 1 |
| Cazzato, G | 1 |
| Bava, A | 1 |
| Joshi, H | 1 |
| Parle, M | 1 |
| Jolles, J | 1 |
| Verhoeven, WM | 1 |
| Gertz, HJ | 1 |
| Kanowski, S | 1 |
| Spagnoli, A | 1 |
| Tognoni, G | 1 |
| Branconnier, RJ | 1 |
| Vencovský, E | 1 |
| Hronek, J | 1 |
| Drahokoupil, L | 1 |
| Fait, V | 1 |
| Hudcová, T | 1 |
| Laciga, Z | 1 |
| Vanková, H | 1 |
| Friedman, E | 1 |
| Sherman, KA | 1 |
| Ferris, SH | 2 |
| Reisberg, B | 1 |
| Bartus, RT | 1 |
| Schneck, MK | 1 |
| Kent, S | 1 |
| Stoppe, G | 1 |
| Sandholzer, H | 1 |
| Staedt, J | 1 |
| Winter, S | 1 |
| Kiefer, J | 1 |
| Rüther, E | 1 |
| Ojer Tsakiridu, D | 1 |
| Dosantos Hernández, JO | 1 |
| Larrabe Medina, J | 1 |
| Sánchez Casado, JI | 1 |
| Sologuren Echenagusia, A | 1 |
| Dormehl, IC | 1 |
| Jordaan, B | 1 |
| Oliver, DW | 1 |
| Croft, S | 1 |
| Flicker, L | 2 |
| Grimley Evans, J | 1 |
| Tariska, P | 1 |
| Paksy, A | 1 |
| Grimley Evans, G | 1 |
| Waegemans, T | 1 |
| Wilsher, CR | 1 |
| Danniau, A | 1 |
| Kurz, A | 1 |
| Winblad, B | 1 |
| Lloyd-Evans, S | 2 |
| Brocklehurst, JC | 2 |
| Palmer, MK | 2 |
| Abuzzahab, FS | 1 |
| Merwin, GE | 1 |
| Zimmermann, RL | 1 |
| Sherman, MC | 1 |
| Petrie, WM | 1 |
| Ban, TA | 1 |
| Gustafson, L | 1 |
| Risberg, J | 1 |
| Johanson, M | 1 |
| Fransson, M | 1 |
| Maximilian, VA | 1 |
| Houillon, P | 1 |
| Kitenge, A | 1 |
| Jouannigot, R | 1 |
| Lullien, L | 1 |
| Cadic, F | 1 |
| Kretschmar, JH | 1 |
| Kretschmar, CH | 1 |
| Herrmann, WM | 3 |
| Stephan, K | 2 |
| Vernon, MW | 1 |
| Sorkin, EM | 1 |
| Nicholson, CD | 1 |
| Sinforiani, E | 1 |
| Iannuccelli, M | 1 |
| Mauri, M | 1 |
| Costa, A | 1 |
| Merlo, P | 1 |
| Bono, G | 1 |
| Nappi, G | 1 |
| Klawans, HL | 1 |
| Genovese, N | 1 |
| Orgogozo, JM | 1 |
| Spiegel, R | 1 |
| Ohtomo, E | 1 |
| Hirai, S | 1 |
| Kern, U | 1 |
| Itil, TM | 1 |
| Menon, GN | 1 |
| Songar, A | 1 |
| Itil, KZ | 1 |
| Porsolt, RD | 1 |
| Lenègre, A | 1 |
| Avril, I | 1 |
| Stéru, L | 1 |
| Doumont, G | 1 |
| Parnetti, L | 1 |
| Ciuffetti, G | 1 |
| Mercuri, M | 1 |
| Senin, U | 1 |
| Hollister, LE | 1 |
| Borromei, A | 1 |
| Gaggi, R | 1 |
| Giancola, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Brain Changes in Pediatric Obstructive Sleep Apnea[NCT05368077] | 70 participants (Anticipated) | Interventional | 2022-05-14 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for piracetam and Dementia
| Article | Year |
|---|---|
[Psychopharmacologic treatment of cognitive function disorders in aging persons: current possibilities].
Topics: Adrenocorticotropic Hormone; Aged; Alzheimer Disease; Anticonvulsants; Brain; Catecholamines; Cholin | 1984 |
'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders.
Topics: Adult; Aged; Cerebrovascular Disorders; Cinnarizine; Clinical Trials as Topic; Cytidine Diphosphate | 1983 |
The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia.
Topics: Aged; Brain; Dementia; Dihydroergotoxine; Humans; Meclofenoxate; Nafronyl; Piracetam; Pyrithioxin; V | 1983 |
[Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review].
Topics: Aged; Aged, 80 and over; Dementia; Double-Blind Method; Humans; Nimodipine; Nootropic Agents; Pirace | 1996 |
Piracetam for dementia or cognitive impairment.
Topics: Alzheimer Disease; Cognition Disorders; Dementia; Humans; Nootropic Agents; Piracetam | 2000 |
Piracetam for dementia or cognitive impairment.
Topics: Alzheimer Disease; Cognition Disorders; Cross-Over Studies; Dementia; Humans; Nootropic Agents; Pira | 2001 |
Clinical efficacy of piracetam in cognitive impairment: a meta-analysis.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Dementia; Double-Blind Method; Humans; Neuroprotective | 2002 |
Drugs in geropsychiatry.
Topics: Aged; Anticoagulants; Central Nervous System Agents; Dementia; Dihydroergotoxine; Humans; Hypnotics | 1978 |
Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders.
Topics: Aged; Animals; Brain; Cognition Disorders; Dementia; Humans; Memory; Middle Aged; Piracetam | 1991 |
Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.
Topics: Animals; Dementia; Humans; Piracetam; Psychotropic Drugs | 1990 |
Pharmacology of dementia.
Topics: 4-Aminopyridine; Acetylcholine; Adenosine Triphosphate; Aged; Aminopyridines; Central Nervous System | 1986 |
Critical review of clinical trials in senile dementia--I.
Topics: Central Nervous System Stimulants; Clinical Trials as Topic; Dementia; Humans; Meclofenoxate; Pirace | 1987 |
[Recent drug therapy of senile dementia].
Topics: Adrenocorticotropic Hormone; Alzheimer Disease; Choline; Dementia; Dihydroergotoxine; Humans; Narcot | 1987 |
16 trials available for piracetam and Dementia
| Article | Year |
|---|---|
Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study.
Topics: Aged; Caregivers; Cost of Illness; Dementia; Female; Humans; Male; Mental Status Schedule; Middle Ag | 2003 |
'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders.
Topics: Adult; Aged; Cerebrovascular Disorders; Cinnarizine; Clinical Trials as Topic; Cytidine Diphosphate | 1983 |
[Clinical experience with treatment by piracetam in gerontopsychiatry (author's transl)].
Topics: Aged; Clinical Trials as Topic; Dementia; Female; Humans; Intracranial Arteriosclerosis; Male; Neuro | 1980 |
SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs.
Topics: Administration, Oral; Aged; Aging; Brain; Cerebellum; Cerebrovascular Circulation; Cognition; Cross- | 1999 |
[Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cognition Disorders; Dementia; Dementia, Vasc | 2000 |
Assessment of drug therapy in chronic brain failure.
Topics: Activities of Daily Living; Aged; Arteriosclerosis; Clinical Trials as Topic; Dementia; Double-Blind | 1978 |
A double-blind investigation of piracetam (nootropil) versus placebo in the memory of geriatric inpatients.
Topics: Aged; Clinical Trials as Topic; Dementia; Double-Blind Method; Female; Humans; Male; Piracetam; Pyrr | 1978 |
Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia.
Topics: Aged; Cerebrovascular Circulation; Clinical Trials as Topic; Dementia; Double-Blind Method; Female; | 1978 |
Piracetam in chronic brain failure.
Topics: Arteriosclerosis; Chronic Disease; Dementia; Double-Blind Method; Female; Humans; Male; Piracetam; P | 1979 |
[On the dose-effect relationship in the therapy with piracetam (author's transl)].
Topics: Aged; Clinical Trials as Topic; Dementia; Dose-Response Relationship, Drug; Female; Humans; Male; Pi | 1976 |
Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam.
Topics: Aged; Aged, 80 and over; Bias; Dementia; Dementia, Multi-Infarct; Double-Blind Method; Factor Analys | 1992 |
Efficacy and clinical relevance of cognition enhancers.
Topics: Acetylcarnitine; Clinical Trials as Topic; Cognition; Cognition Disorders; Dementia; Humans; Nimodip | 1991 |
Pharmacology of dementia.
Topics: 4-Aminopyridine; Acetylcholine; Adenosine Triphosphate; Aged; Aminopyridines; Central Nervous System | 1986 |
Critical review of clinical trials in senile dementia--I.
Topics: Central Nervous System Stimulants; Clinical Trials as Topic; Dementia; Humans; Meclofenoxate; Pirace | 1987 |
[Nootropic drugs: effects and effectiveness. A reflection exemplified by a phase III study using piracetam].
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Dementia; Double-Blind Method; Female; Humans; Ma | 1987 |
Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifylline.
Topics: Aged; Clinical Trials as Topic; Dementia; Drug Therapy, Combination; Female; Humans; Male; Mental Re | 1985 |
16 other studies available for piracetam and Dementia
| Article | Year |
|---|---|
Intermittent catatonia and complex automatisms caused by frontal lobe epilepsy in dementia.
Topics: Aged, 80 and over; Anticonvulsants; Automatism; Catatonia; Dementia; Diagnosis, Differential; Electr | 2017 |
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan.
Topics: Cohort Studies; Dementia; Dihydroergocristine; Dihydroergotamine; Donepezil; Galantamine; Humans; In | 2015 |
The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy.
Topics: Adult; Anticonvulsants; Dementia; Disease Progression; Down Syndrome; Epilepsy; Female; Humans; Leve | 2017 |
Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET.
Topics: Aged, 80 and over; Aging; Alcohol Drinking; Antihypertensive Agents; Cognition Disorders; Dementia; | 2009 |
Evaluation of nootropic potential of Ocimum sanctum Linn. in mice.
Topics: Alzheimer Disease; Amnesia; Animals; Dementia; Diazepam; Dose-Response Relationship, Drug; Humans; M | 2006 |
[Therapy of senile dementia of the Alzheimer type and multi-infarct dementia].
Topics: Alzheimer Disease; Animals; Brain; Cerebrovascular Circulation; Combined Modality Therapy; Dementia; | 1983 |
Clinical response to choline plus piracetam in senile dementia: relation to red-cell choline levels.
Topics: Choline; Dementia; Drug Therapy, Combination; Erythrocytes; Humans; Piracetam; Pyrrolidinones | 1981 |
Preventing senile dementia: hope for the future.
Topics: Aged; Choline; Dementia; Dihydroergotoxine; Female; Humans; Male; Memory; Middle Aged; Piracetam | 1981 |
Prescribing practice with cognition enhancers in outpatient care: are there differences regarding type of dementia?--Results of a representative survey in lower Saxony, Germany.
Topics: Adult; Alzheimer Disease; Ambulatory Care; Data Collection; Dementia; Dementia, Vascular; Female; Ge | 1996 |
[Various therapeutic effects of piracetam (1st part)].
Topics: Aged; Animals; Dementia; Female; Humans; Intellectual Disability; Piracetam; Pyrrolidinones | 1979 |
Neuropsychological changes in demented patients treated with acetyl-L-carnitine.
Topics: Acetylcarnitine; Aged; Brain Ischemia; Carnitine; Dementia; Female; Humans; Male; Middle Aged; Pirac | 1990 |
[Drug therapy of Alzheimer's disease. Problems of the criteria of clinical trials of nootropic drugs].
Topics: Clinical Trials as Topic; Dementia; Humans; Piracetam; Pyrrolidinones | 1988 |
CNS pharmacology and clinical therapeutic effects of oxiracetam.
Topics: Brain; Dementia; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Electroencephal | 1986 |
The effects of exifone, a new agent for senile memory disorder, on two models of memory in the mouse.
Topics: Amnesia; Animals; Avoidance Learning; Benzophenones; Dementia; Exploratory Behavior; Habituation, Ps | 1987 |
Alzheimer's disease. Is it worth treating?
Topics: Aged; Alzheimer Disease; Dementia; Dihydroergotoxine; Humans; Nafronyl; Papaverine; Pentoxifylline; | 1985 |
Involutional dementias: new perspectives.
Topics: Aged; Dementia; Drug Therapy, Combination; Humans; Middle Aged; Neurocognitive Disorders; Phosphatid | 1985 |